Search clinical trials for: ABBV-400

Total 12614 results

AbbVie

Available

Expanded Access to ABBV-400

Non-Small Cell Lung Cancer
AbbVie

Completed

A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy

Ulcerative Colitis (UC)

United States, Canada, France, Germany, Hungary, Italy, Korea, Republic of, Netherlands, Spain, United Kingdom
AbbVie

Recruiting

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

Hepatocellular Carcinoma | Triple Negative Breast Cancer | Pancreatic Ductal Adenocarcinoma | Esophageal Squamous Cell Carcinoma | Biliary Tract Cancers | Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer | Head and Neck Squamous-Cell Carcinoma

United States, Israel, Japan, Puerto Rico
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

Tolerability and Pharmacokinetics of CSPCHA115 Capsules in Chinese Healthy Volunteers

Asthma; Allergic Rhinitis

China
Guangdong Zhongsheng Pharmaceutical Co., Ltd.

Completed

The Safety, Tolerability and Pharmacokinetic Study of ZSP1273 in Healthy Volunteers.

Influenza

China
JMackem Co., Ltd
Seoul National University Hospital

Recruiting

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Oral Administration of AJH-2947 in Healthy Korean and/or Caucasian Adult Male Subjects

Diabetic Neuropathies | Neuropathic Pain | Post Herpetic Neuralgia

Korea, Republic of
Yungjin Pharm. Co., Ltd.

Completed

Safety, Tolerability and Pharmacokinetic Study of KL1333 in Healthy Male Volunteers

MELAS Syndrome | Mitochondrial Respiratory Chain Deficiencies

Korea, Republic of
Gannex Pharma Co., Ltd.
Ascletis Pharmaceuticals Co., Ltd.

Recruiting

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC61in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

United States
AbbVie

Completed

A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222

Cystic Fibrosis

United States, Belgium, Canada, Czechia, France, Hungary, Netherlands, New Zealand, Poland, Slovakia, United Kingdom, Serbia
AbbVie

Terminated

A Study to Assess the Effects of Multiple Study Drug Regimens in Subjects With Newly Diagnosed Locally Advanced Head and Neck Squamous Cell Carcinoma

Head and Neck Cancer

United States
Ilkos Therapeutic Inc.

Completed

Dose-response Relationship Study of S42909 on Leg Ulcer Healing

Venous Leg Ulcer

Spain, Hungary, Canada, United States, Brazil, Argentina, Austria, Czechia, Italy, Poland, Slovakia
AbbVie

Completed

Study to Assess Adverse Events and How Intravenous (IV) ABBV-47D11 and IV ABBV-2B04 Given Alone and in Combination Moves Through the Body of Adult Participants With Coronavirus Disease 2019 (COVID-19)

CoronaVirus Disease-2019 (COVID-19)

United States, Hungary, Israel, Netherlands, Puerto Rico
AbbVie

Active, not recruiting

Study to Evaluate Adverse Events, Change in Disease Activity, Movement of Oral ABBV-623 and ABBV-992 Tablets in the Body of Adult Participants With B-cell Cancers

B-cell Lymphoma

Israel, Puerto Rico, Turkey
AbbVie

Completed

A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors

Advanced Solid Tumors Cancer

United States, France, Japan, Puerto Rico, Spain, Taiwan
Aevi Genomic Medicine, LLC, a Cerecor company

Completed

Pharmacokinetic and Tolerability Study of NFC-1 in Subjects Aged 6-17 Years With ADHD

Attention Deficit Disorder With Hyperactivity

United States
AbbVie

Withdrawn

A Study to Evaluate the Safety and Tolerability of ABBV-0805 in Patients With Parkinson's Disease

Parkinson's Disease

United States, Puerto Rico
AbbVie

Recruiting

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD)

Healthy Volunteers | Generalized Anxiety Disorder (GAD) | Bipolar Disorder (BPD)

United States
AbbVie

Completed

Study to Assess Adverse Events and How Intravenous (IV) or Subcutaneous (SC) ABBV-382 Moves Through the Body of Adult Participants With Human Immuno-Deficiency Virus (HIV-1)

Human Immunodeficiency Virus (HIV)

United States, Puerto Rico
AbbVie

Completed

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-157 in Healthy Volunteers and in Participants With Chronic Plaque Psoriasis

Psoriasis

United States
Pfizer

Withdrawn

A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis

Ulcerative Colitis

United States
GlaxoSmithKline

Completed

A Dose Ranging Study to Evaluate the Safety and Efficacy of GSK2586184 in Patients With Chronic Plaque Psoriasis

Psoriasis

Germany, United Kingdom
Guangdong Raynovent Biotech Co., Ltd

Completed

Study of ZSP1273 in Patients With Acute Uncomplicated Influenza A

Influenza A

China
AbbVie

Recruiting

Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease

Alzheimer's Disease (AD)

United States, Japan, New Zealand, Australia, Spain, Germany, United Kingdom
AbbVie

Active, not recruiting

A Study to Evaluate Adverse Events and How Single Ascending Doses of ABBV-141 Move Through the Body of Healthy Adult Western and Asian Participants

Healthy Volunteers

United States
AbbVie

Terminated

A Study to Assess Pharmacokinetics, Safety, and Tolerability of ABBV-903 in Healthy Japanese and Han Chinese Participants

Healthy Volunteers

United States
AbbVie

Completed

A Study to Assess How Food Affects the Safety and Pharmacokinetics of Galicaftor and Navocaftor (M23-492 FE)

Healthy Volunteers

United States
AbbVie

Terminated

Study to Assess Adverse Events and How Oral ABBV-990 Moves Through the Body of Adult Healthy Participants

Healthy Volunteers

United States
AbbVie

Recruiting

A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors

Solid Tumors

United States, Israel
CymaBay Therapeutics, Inc.

Completed

Study Investigating the Safety, Tolerability, and PK, PD, of CB-0406

Healthy Volunteers

Australia
AbbVie

Completed

A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer

Small Cell Lung Cancer

United States, Japan, Korea, Republic of, Taiwan
Ridgeback Biotherapeutics, LP
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19

SARS-CoV-2 Infection, COVID-19

United States
AbbVie

Recruiting

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABBV-1088 Oral Dose in Healthy Adult Participants.

Healthy Volunteers

United States
AbbVie

Not yet recruiting

Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma
AbbVie

Terminated

Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic Fibrosis

Cystic Fibrosis (CF)

United States, Australia, Belgium, Hungary, Netherlands, New Zealand, Slovakia, United Kingdom
Merck Sharp & Dohme LLC

Completed

A Multiple-Dose Study to Evaluate MK-1075 in Hepatitis C Virus (HCV) Infected Participants (MK-1075-004)

Hepatitis C Virus Infection
Innovation Pharmaceuticals, Inc.

Completed

Efficacy and Safety of Prurisol Administered Orally for Active Moderate to Severe Chronic Plaque Psoriasis

Chronic Stable Plaque Psoriasis

United States
AbbVie

Active, not recruiting

A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors

Advanced Solid Tumors Cancer

United States, Australia, Canada, France, Japan, Korea, Republic of, Spain
AbbVie

Recruiting

A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382

Human Immuno-deficiency Virus (HIV) Disease

United States, Puerto Rico, Japan, Spain, Germany, Canada, Belgium, France, Poland, South Africa
Lexicon Pharmaceuticals

Completed

A Study to Determine the Safety and Efficacy of LX3305 in Subjects With Active Rheumatoid Arthritis

Rheumatoid Arthritis

United States
AbbVie

Recruiting

A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer

United States, Israel
AbbVie

Completed

A Study to Assess the Adverse Events and How Oral ABBV-552 Capsules Moves Through the Body of Healthy Adult Japanese and Han Chinese Participants

Healthy Volunteers

United States
AbbVie

Terminated

A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers

Cancer | Non Small Cell Lung Cancer | Acute Myeloid Leukemia (AML)

United States, France, Israel, Japan, United Kingdom
AbbVie

Terminated

A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With Relapsed/Refractory (R/R) Multiple Myeloma

Cancer | Multiple Myeloma (MM)

United States, Australia, France, Israel, Japan, Spain, Taiwan
AbbVie

Terminated

A Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Participants With Relapsed/Refractory Acute Myeloid Leukemia (AML) Cancer

Acute Myeloid Leukemia (AML)

United States
Galapagos NV

Completed

A Study to Evaluate Multiple Doses of GLPG2222 in Adult Subjects With Cystic Fibrosis

Cystic Fibrosis

Spain, United Kingdom, United States, Netherlands, Belgium, Serbia
GlaxoSmithKline

Terminated

An Adaptive Phase II Study to Evaluate the Efficacy, Pharmacodynamics, Safety and Tolerability of GSK2586184

Systemic Lupus Erythematosus

Estonia, Germany, South Africa, Peru, Sweden, France, Korea, Republic of, Hong Kong, Spain, Romania, Czechia, Argentina, Chile, Hungary, Greece, Poland
CVI Pharmaceuticals

Unknown

Safety and Efficacy of CVI-LM001 in Patients With Hypercholesterolemia

Hyperlipidemia

China
AbbVie

Active, not recruiting

A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused ABBV-383 of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan

Relapsed/Refractory Multiple Myeloma

Japan
AbbVie

Recruiting

Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors

Advanced Solid Tumors Cancer

United States, Australia, Israel, Japan, Korea, Republic of, Puerto Rico, Spain, Taiwan, Canada, France, Belgium
AbbVie

Completed

A Study to Assess the Relative Bioavailability of Immediate Release Formulations of ABBV-903 in Healthy Adult Participants

Healthy Volunteer

United States

3

Subscribe